biostudies-literatureTherriault JNIA NIH HHSEuropean Union Joint Program for Neurodegenerative DisordersSwedish Research CouncilHjärnfonden, SwedenSwedish Alzheimer FoundationWeston Brain FoundationCanadian Institutes of Health ResearchAlzheimer’s AssociationAlzheimer Drug Discovery Foundation (ADDF), USAEuropean Research CouncilFonds de Recherche du Québec–SantéUK Dementia Research InstituteSwedish government and the County Councils, the ALF-agreementSwedish State Support for Clinical Researchfcab136https://www.ebi.ac.uk/biostudies/studies/S-EPMC8249102biostudies-literatureUnknown3(3)Alzheimer's disease is the leading cause of dementia worldwide and is characterized by a long preclinical phase in which amyloid-β and tau accumulate in the absence of cognitive decline. <i>In vivo</i> biomarkers for Alzheimer's disease are expensive, invasive and inaccessible, yet are critical for accurate disease diagnosis and patient management. Recent ultrasensitive methods to measure plasma phosphorylated tau 181 (p-tau181) display strong correlations with tau positron emission tomography, p-tau181 in CSF, and tau pathology at autopsy. The clinical utility of plasma-based p-tau181 biomarkers is unclear. In a longitudinal multicentre observational study, we assessed 1113 non-demented individuals (509 cognitively unimpaired elderly and 604 individuals with mild cognitive impairment) froBrain communicationsAssociation of plasma P-tau181 with memory decline in non-demented adults.PMC8249102#681712JPND2019-466–236#2018–02532#201809–2016862#AF-742881#ALFGBG-720931U19 AG024904#ALFGBG-7159862020-VICO-279314#2017–00915#FO2017-0243720931#RDAPB-201809–2016615681712MOP-11–51-3NIRP-12–259245U01 AG024904NIRG-12–92090Gauthier SSaha-Chaudhuri PRosa-Neto PTissot CMathotaarachchi SZetterberg HAshton NJAlzheimer’s Disease Neuroimaging InitiativeBezgin GChamoun MPascoal TABenedet ALTherriault JKarikari TKBlennow KLussier FZfalseAssociation of plasma P-tau181 with memory decline in non-demented adults.Alzheimer's disease is the leading cause of dementia worldwide and is characterized by a long preclinical phase in which amyloid-β and tau accumulate in the absence of cognitive decline. <i>In vivo</i> biomarkers for Alzheimer's disease are expensive, invasive and inaccessible, yet are critical for accurate disease diagnosis and patient management. Recent ultrasensitive methods to measure plasma phosphorylated tau 181 (p-tau181) display strong correlations with tau positron emission tomography, p-tau181 in CSF, and tau pathology at autopsy. The clinical utility of plasma-based p-tau181 biomarkers is unclear. In a longitudinal multicentre observational study, we assessed 1113 non-demented individuals (509 cognitively unimpaired elderly and 604 individuals with mild cognitive impairment) fro2021-01-01T00:00:00Z2021 Jul2026-05-07T20:36:17.545Z2022-02-10T18:28:27.554ZS-EPMC82491023422287510.1093/braincomms/fcab136